Researchers Call for Expansion of Mint Tobacco Ban

Dec.08.2022
Researchers Call for Expansion of Mint Tobacco Ban
Researchers urge FDA to expand ban on mint-flavored tobacco products to include potential substitutes like mint pipes and cigarillos.

Researchers from the Rutgers Tobacco Research Center and Ohio State University are calling for the US Food and Drug Administration (FDA) to expand the ban on mint-flavored cigarettes and cigars to include potential alternatives like mint-flavored pipes and rolling papers.


According to a study published in the journal Tobacco Control, researchers are urging the FDA to maximize the benefits of the ban on menthol-flavored cigarettes based on new evidence showing that these alternatives are attractive and have the potential to be addictive for adults who smoke menthol cigarettes.


Andrea Villanti, Associate Director of the Rutgers University Tobacco Research Center, stated that tobacco companies have renamed their roll-your-own tobacco as pipe tobacco to avoid taxes, and have branded flavored cigarettes as flavored cigars to evade federal bans. Villanti, the lead researcher of the study, said, "We have seen companies promoting pipe tobacco and cigarillos alongside cigarettes and filtered cigars. The products we tested in our research are likely the ones tobacco companies will promote after mint-flavored cigarettes are banned.


Researchers examined 98 adults who smoked menthol cigarettes to compare the addictive potential of combustible menthol with its substitutes. The study was conducted in four parts over a three-week period, during which participants first smoked their usual brand of menthol cigarettes. In the next three sessions, participants were randomly assigned three different menthol cigarette substitutes:


One cigarette that does not contain menthol alcohol is a pre-assembled menthol cigarette made with mint tobacco and a menthol pipe for filtering. It also includes a small menthol cigar.


During each meeting, researchers measured the smoking habits of participants, including the amount of carbon monoxide emitted, cravings, and withdrawal symptoms. Participants also self-reported their perceived effects of the drug and evaluated other measures of addiction potential for each product.


The team discovered that while menthol-filtered small cigars and non-mentholated cigarettes are attractive alternatives to menthol cigarettes, menthol pipe tobacco and rolling papers are the most alluring and lead to the highest number of indicators for future nicotine addiction. However, these products have not been considered for inclusion in the proposed ban.


According to the investigation results, the components of menthol cigarette products, including menthol paper, cigarette tube, and tobacco for pipe, should be included in the standards for menthol cigarettes and flavored cigars, as stated by Villanti.


Previous research has established a correlation between the use of menthol-flavored cigarettes and an increase in smoking initiation, nicotine dependence, and reduced adult smoking cessation, particularly among vulnerable populations. The FDA has proposed a regulation prohibiting the use of menthol as a flavoring agent in cigarettes and cigars to address this public health concern. Following a review of public feedback, a final decision is expected to be made in the coming months.


Currently, research results indicate that the components of menthol cigarette products, including menthol cigarette paper, filters, and tobacco, should be included in the standards for menthol cigarettes and flavored cigars," said Theodore Wagener, director of the center. The research was conducted by the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and the lead author of the study. "Failing to comply with this restriction would result in a serious loophole that the tobacco industry has already exploited and could potentially weaken the potential public health benefits of the proposed menthol ban.


2FIRSTS will continue to provide ongoing coverage of this topic, with further updates available on the "2FIRSTSAPP" platform. Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus distributor H&S said the zero-nicotine, zero-tar NEO vaping line will begin rolling out across FamilyMart stores in Japan from September 14, 2026, excluding some locations. The DASH line will also be sold at selected FamilyMart stores in southern Kyushu and Okinawa. Snowplus simultaneously named Japanese rock band Kishidan as a brand ambassador, combining convenience-store distribution with a broader consumer marketing push in Japan.
Sep.15
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia’s Department of Home Affairs has hired Deloitte to provide data analytics, business-process, communications and project-delivery support to the Office of the Illicit Tobacco and E-Cigarette Commissioner. The government says Deloitte personnel do not provide policy advice to the Commissioner or the Australian government, with policy development and decision-making remaining with public officials. The arrangement has nevertheless drawn scrutiny because Deloitte has previously provided professional services to several tobacco and vaping companies.
Sep.03
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
Product | KT&G Brings LOOP Nicotine Pouches to South Africa, Supporting ASF’s Expansion Across Africa
Product | KT&G Brings LOOP Nicotine Pouches to South Africa, Supporting ASF’s Expansion Across Africa
KT&G has introduced nicotine pouch brand LOOP in South Africa, expanding its modern oral nicotine portfolio. Developed by Swedish company Another Snus Factory (ASF), LOOP is a tobacco-free nicotine pouch brand. KT&G and U.S. tobacco company Altria previously participated in ASF’s strategic development, and the South Africa launch represents a further step in LOOP’s international expansion.
Aug.06
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
Germany collected €9.789 billion in total tobacco tax revenue from January through August 2026, down 10.8% from a year earlier, according to the Federal Ministry of Finance. Germany's tobacco tax base covers not only cigarettes and fine-cut tobacco but also heated tobacco and vaping liquids taxed as tobacco substitutes. The German Association of the Tobacco Industry and Novel Products, or BVTE, citing federal statistical data, said tax-paid cigarette volume fell 12.6% to 40.6 billion sticks. BVTE is using the latest figures to argue against further tax increases planned from 2027 through 2030, while Germany's parliament is scheduled to hold a first reading of the bill on September 24.
Sep.23